Financial Review: Peak Pharmaceuticals (OTCMKTS:PKPH) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS)

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Profitability

This table compares Cyclacel Pharmaceuticals and Peak Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
Peak Pharmaceuticals	N/A	N/A	-159.55%

Analyst Ratings

This is a breakdown of current ratings and price targets for Cyclacel Pharmaceuticals and Peak Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Peak Pharmaceuticals	0	0	0	0	0.00

Valuation and Earnings

This table compares Cyclacel Pharmaceuticals and Peak Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750,000.00	6.73	-$3.00 million	($4.54)	-0.20
Peak Pharmaceuticals	N/A	N/A	-$160,000.00	N/A	N/A

Peak Pharmaceuticals has lower revenue, but higher earnings than Cyclacel Pharmaceuticals.

Insider & Institutional Ownership

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.7% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 18.4% of Peak Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Cyclacel Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Summary

Cyclacel Pharmaceuticals beats Peak Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

About Peak Pharmaceuticals

Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.